New Funding Source For Cash-Strapped BioPharma
This article was originally published in The Pink Sheet Daily
Executive Summary
New ‘growth equity’ focus at Novo A/S to fund late-stage and commercially focused life sciences companies
You may also be interested in...
Venture Capital Firms Looking For Plan B
Companies are cheap, but money is expensive. Burn must be slowed, but without sacrificing value drivers. And finding the exit has never been more difficult. Can venture investors make the best of the worst of times
Venture Capital Firms Looking For Plan B
Companies are cheap, but money is expensive. Burn must be slowed, but without sacrificing value drivers. And finding the exit has never been more difficult. Can venture investors make the best of the worst of times
Biopharma in 2008: What a Difference an Economic Crisis Makes
Even before the financial meltdown, 2008 was a remodeling year for the biopharmaceutical world. Many pharma companies, more reliant on the product candidates and technologies of the biotech world than ever, were pinned down by excess infrastructure and lagging productivity. But when the world's cash dried up, so, too, did biotech's leverage over those downtrodden in-licensers and acquirers. We highlight some top trends from a difficult year that may shape industry in 2009 and beyond.